Recruiting

NCT Number: NCT07342920

Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.

Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention.

This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cystic Fibrosis Behavior Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases Smoking Vaping

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Pneumologie - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Romain KESSLER, MD, PhD

PRINCIPAL_INVESTIGATOR

Romain Kessler, MD, PhD

CONTACT

[email protected]

33 3 69 55 03 77

Sophie TAUPIN, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient (≥ 18 years old)
With confirmed cystic fibrosis
Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center

Exclusion criteria

Patients who have undergone a double lung transplant for cystic fibrosis.

Treatment and study plan

Primary outcomes

Prevalence of smoking in adults with cystic fibrosis

Time frame: Up to 12 months

The proportion of adults with cystic fibrosis who smoke:

Example:

If 10 out of 100 adults with cystic fibrosis smoke, then the prevalence of smoking in this group is 10%.

Study contacts

Contact information is provided by the study sponsor or research team.

Romain Kessler, MD, PhD

CONTACT

[email protected]

33 3 69 55 03 77

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: Taba-Muco

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jan 15, 2026
Registry last updated: Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting